Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

開 拓 藥 業 有 限 公 司 *

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

RESIGNATION OF CHIEF FINANCIAL OFFICER, JOINT COMPANY SECRETARY AND PROCESS AGENT, APPOINTMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF PROCESS AGENT

RESIGNATION OF CHIEF FINANCIAL OFFICER, JOINT COMPANY SECRETARY AND PROCESS AGENT

The board (the "**Board**") of directors ("**Directors**") of Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Ming Ming Cheung ("**Mr. Cheung**") has resigned as the chief financial officer and a joint company secretary of the Company due to personal career development planning. Mr. Cheung has also ceased to act as the authorised representative of the Company for the acceptance of service of process or notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "**Process Agent**"), in each case, with effect from 21 September 2026.

Mr. Cheung has confirmed that he has no disagreement with the Board and there are no other matters in connection with his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company. The Board is of the view that Mr. Cheung's resignation will not have any material adverse impact on the financial operations and management of the Group.

Following Mr. Cheung's resignation, Mr. Wai Chiu Wong, the other joint company secretary of the Company who is qualified to act as the company secretary of the Company under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, will remain in office and continue to serve as the sole company secretary of the Company with effect from 21 September 2026.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Cheung for his valuable contributions to the Company during his tenure.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board further announces that following Mr. Cheung's resignation, Mr. Joseph H J Cheng ("**Mr. Cheng**") has been appointed as the chief financial officer of the Company, with effect from 21 September 2026. The biographical details of Mr. Cheng are set out below:

Mr. Cheng, aged 48, is primarily responsible for overseeing capital markets, international business, financial planning, investment, internal control, investor relations and public relations of the Group following his appointment as the chief financial officer of the Company.

Mr. Cheng has over 20 years of experience in global capital markets, corporate finance, and strategic management. Prior to joining the Group, he held various positions, including senior executive roles, across international financial institutions and cross-border enterprises. From 2024 to 2026, Mr. Cheng served as a partner at TH Capital. From 2015 to 2024, he served as an independent financial advisor for various pre-IPO companies. From 2011 to 2015, he served as the head of investor relations at 21Vianet. From 2007 to 2011, he co-founded and operated Cooffer. From 2003 to 2007, he worked as a trader at Compagnie Financière Tradition and Bank of America, respectively.

Mr. Cheng obtained a Bachelor of Arts in Economics from Rutgers University in 2002 and subsequently earned a Master of Business Administration (MBA) from University of Maryland in 2010.

APPOINTMENT OF PROCESS AGENT

The Board hereby further announces that Ms. Lin Sio Ngo ("**Ms. Lin**") has been appointed as the Process Agent following the resignation of Mr. Cheung as his replacement with effect from 21 September 2026.

The Board would like to extend a warm welcome to Mr. Cheng and Ms. Lin on their new appointments.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 21 September 2026

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Yunfei Chen and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*